The activities of hundreds, perhaps thousands, of metabolites are regulated by human cytosolic sulfotransferases (SULTs) -a 13-member family of disease relevant enzymes that catalyze transfer of the sulfuryl moiety (-SO 3 ) from PAPS (3′-phosphoadenosine 5′-phosphosulfonate) to the hydroxyls and amines of acceptors. SULTs harbor two independent allosteric sites, one of which, the focus of this work, binds non-steroidal anti-inflammatory drugs (NSAIDs). The structure of the first NSAID-binding site -that of SULT1A1 -was elucidated recently and homology modeling suggest that variants of the site are present in all SULT isoforms. The objective of the current study was to assess whether the NSAID-binding site can be used to regulate sulfuryl transfer in humans in an isoform specific manner. Mefenamic acid (Mef) is a potent (K i 27 nM) NSAID-inhibitor of SULT1A1 -the predominant SULT isoform in small intestine and liver. Acetaminophen (APAP), a SULT1A1 specific substrate, is extensively sulfonated in humans. Dehydroepiandrosterone (DHEA) is specific for SULT2A1, which we show here is insensitive to Mef inhibition. APAP and DHEA sulfonates are readily quantified in urine and thus the effects of Mef on APAP and DHEA sulfonation could be studied non-invasively. Compounds were given orally in a single therapeutic dose to a healthy, adult male human with a typical APAP-metabolite profile. Mef profoundly decreased APAP sulfonation during first pass metabolism and substantially decreased systemic APAP sulfonation without influencing DHEA sulfonation; thus, it appears the NSAID site can be used to control sulfonation in humans in a SULT-isoform specific manner.
Introduction
Thyroid hormone (TH) regulates energy metabolism and development in humans [1] . TH is extensively sulfonated, which prevents THreceptor binding and dramatically increases the efficiency with which TH is inactivated by Type 1 deiodinase [2] [3] [4] . Inhibition of SULT1A1 -the isoform that sulfonates TH -is expected to slow TH inactivation, and could thus prove of value in treating hypothyroidism. Further, in clinical studies, elevated intratumoral expression of SULT2B1b in colorectal cancer patients is highly correlated with increased invasion and metastasis, and early recurrence and death [5] . 2B1b expression in colorectal cell lines correlates positively with enhanced colony formation, migration and invasion [5, 6] . Here again, an isoform specific SULT inhibitor might prove of value. Finally, liver X receptors (LXRs) are pivotal in regulating cholesterol homeostasis. Oxysterols are primary endogenous LXR agonists and are transformed by sulfonation into LXR antagonists with enhanced affinities [7] . In liver, SULT2A1 catalyzes the majority of oxysterol sulfonation [8] ; in brain [9] and aorta [10] , SULT2B1b is the dominant isoform. Thus, tissue specific alleviation of LXR inhibition (i.e., LXR activation) could in theory be achieved by selective inhibition of one or the other SULT isoform.
The preceding examples highlight the potential of SULT inhibition in treating human disease; yet, to our knowledge, there are no therapeutics that target sulfuryl-transfer -a situation due, in part, to the challenges associated with selectively inhibiting a single member of ahighly sequence-and structurally-conserved enzyme family [11, 12] . Recently, our group demonstrated that SULTs harbor two physically distinct, non-interacting allosteric pockets [13] -the so-called NSAID [14] and catechin binding sites [15] . The structures of both sites have been determined [14, 15] and homology modeling suggests that variants of the sites are present in each SULT family member. The allosteric sites appear to have evolved to enable molecular communication between a given isoform and the metabolites with its purview. Recent work demonstrated that SULT1A3, which exhibits high specificity for catecholamine neurotransmitters, is allosterically regulated by tetrahydrobiopterin (THB), an essential co-factor in catecholamine biosynthesis. THB exhibits > 20,000-fold selectivity for 1A3 over the other major SULTs in liver and brain [16] . Thus, each allosteric site promises a unique isoform-specific target that can be used to independently regulate metabolism the thirteen metabolic domains in which SULTs operate.
The current study, the first of its kind, uses an NSAID (mefenamic acid, Mef) with high specificity for SULT1A1, the predominant SULT in human liver, to demonstrate that the allostere potently inhibits sulfonation of a 1A1-specific substrate (acetaminophen, APAP) in a healthy adult human without influencing sulfonation of dehydroepiandrosterone (DHEA) -a substrate for SULT2A1, which is a Mef-insensitive isoform also found at high levels in liver. Thus it appears SULT allosteric sites can be used to isoform-specifically regulate SULTs in vivo. In addition, the work reveals that first-pass sulfonation of APAP is virtually completely inhibited by Mef -a finding of some clinical significance -and addresses the potential drug-drug interactions between NSAIDs and drugs sulfonated by SULT1A1.
Materials and methods

Materials
The materials and sources used in this study are as follows: dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA), L-glutathione (reduced), 1-hydroxypyrene (1-HP), imidazole, isopropyl-thio-β-D-galacto-pyranoside (IPTG), LB media, lysozyme, pepstatin A, potassium phosphate, and 3-(trimethylsilyl)propionic-2,2,3,3-d 4 acid (TSP) sodium salt were the highest grade available from Sigma. Ampicillin, HEPES, KCl, KOH, MgCl 2 and phenylmethylsulfonyl fluoride (PMSF) were purchased from Fisher Scientific. Acetaminophen was obtained from CVS Pharmacy, liquid gel tablets, lot 1001402. Dehydroepiandrosterone (DHEA), the chemical, was purchased from TCI America, DHEA [1, 2, 6, H(N)] was obtained from PerkinElmer, DHEA, the nutraceutical, was obtained from the General Nutrition Corporation, lot 57429B17. Mefenamic acid, the chemical, was obtained from Santa Cruz Biotechnology. Mefenamic acid, the drug, was obtained from Lupin Limited, Lot G700974. Deuterium Oxide (> 99%) was purchased from Acros Organics. Glutathione-and nickel-chelating resins were obtained from GE Healthcare. Competent E. coli (BL21(DE3)) was purchased from Novagen. PAPS was synthesized as previously described [17, 18] and was ≥99% pure as assessed by anionexchange HPLC.
Methods
Dosing and sample collection
The following protocol is approved by the Albert Einstein College of Medicine, Institutional Review Board (IRB protocol # 2017-8685) and is registered at ClinicalTrials.gov (NCT03383133). A single, therapeutic dose of acetaminophen (APAP, 1.0 g) or dehydroepiandrosterone (DHEA, 75 mg) was taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (Mef, 0.75 g). The compounds were taken prior to eating. One hour later, a light breakfast was consumed (cereal with milk, and coffee) and normal eating habits were then resumed. Voided urine samples were collected at regular intervals. The first sample was collected at 30′, and samples were collected approximately hourly thereafter. The exact time that each sample was collected was recorded and is reported in the figures. Samples were weighed, and a 10 ml aliquot was removed and stored at −80°C for subsequent study. The time interval between dosing in these experiments was at least 24 hrs (i.e. > 20× reported drug half-life [19] [20] [21] ).
NMR Measurements
1
H NMR spectra were acquired using a Bruker 600 or 900 MHz spectrometer equipped with a TCI H/F-cryogenic probe. Samples (pH 6.9 ± 0.1) were mixed 1:1 (v/v) with D 2 O containing TSP (1.0 mM [22] ). Each spectrum represents the average of 64 spectra acquired using a 1D pulse sequence that included a 4.0 s relaxation delay and 2.73 s acquisition time. Water suppression was accomplished using Excitation Sculpting [23] . Samples were equilibrated, and spectra were acquired at 298 ± 2°K. 600 MHz spectra were collected using the Bruker automated acquisition software ICON-NMR and SampleJet. Peaks were fit to a Lorentzian peak shape using TopSpin3.5 [24] . Metabolite concentrations were determined by normalizing their peak areas to that of the TSP signal [24] .
Protein expression and purification
The SULT1A1 and 2A1 expression plasmids have a PreScissionprotease cleavable, triple-affinity tag (N-His/GST/MBP) fused to the Ntermini of SULT coding regions that are spliced into the multiple cloning site of pGEX-6P [13, [25] [26] [27] . Protein expression is induced by addition of IPTG (0.30 mM, final) to LB/ampicillin (100 mg/L) cultures of E. coli (BL21(DE3)) harboring expression plasmid that were cultured at 37°C to an OD 600 -0.6. Upon IPTG addition, cultures are shifted to 17°C using an ice/water bath and then incubated at 17°C for 18 h. The cells are pelleted, resuspended in Lysis Buffer (PMSF (290 µM), pepstain A (1.5 µM), lysozyme (0.10 mg/ml), EDTA (2.0 mM), KCl (400 mM), KPO 4 (50 mM), pH 7.5), sonicated, and centrifuged (10,000 g, 1.0 hr) at 4°C. , and KPO 4 (25 mM), pH 7.5) overnight at 4°C to remove reduced glutathione, and then run through a GST column to remove the tag. The protein is > 95% pure as judged by SDS-PAGE. The protein is then concentrated and its concentration is determined by UV absorbance (Ɛ 280 1A1 = 53.9 mM
, Ɛ 280 2A1 = 79.5 mM
[ 25, 26] . The final protein is flash frozen and stored at -80°C.
Mef inhibition studies
Mef initial-rate inhibition parameters for SULT1A1 and 2A1 were determined using the well-established 1-HP assay [13] [14] [15] [16] 28, 29] . Reaction progress was monitored via the sulfonation-dependent change in 1-HP fluorescence (λ ex = 325 nm, λ em = 370 nm). Velocities were calculated from the region of the progress curve in which ≤5% of the concentration-limiting substrate (1-HP) consumed at the reaction endpoint was converted to product. Velocities were determined in duplicate, and K i was obtained from least-squares fitting of v vs [S] data using a noncompetitive partial-inhibition model [13, 30] . Mef concentrations ranged from 0.20 to 20 × K i (SULT1A1) and 0.10-10 × K i (SULT2A1). Reactions were initiated by addition of saturating PAPS (0.50 mM, > 16 × K m ) to a solution containing enzyme (10 nM, active site), saturating (40 x K m ) 1-HP (2.0 and 20 µM for SULT1A1 and 2A1, respectively), MgCl 2 (5.0 mM), and KPO 4 (50 mM), pH 7.5, 25 ± 2°C.
Results and discussion
APAP metabolism -a brief overview
In normal adult humans, APAP is extensively metabolized, primarily in liver [31] . The principal APAP metabolic transformations are outlined in Fig. 1 . The major metabolites are the sulfonate and glucuronide conjugates [31] , which along with minor conjugates [20, 21] clear rapidly to urine [19] . Approximately 100% of a therapeutic dose of APAP is recovered in urine; ∼4% as unconjugated APAP [31] . APAP is also converted, via CYP-mediated oxidation, to N-acetyl-p-benzoquinone (NAPQI) -a highly reactive, toxic alkylating agent [32] . APAPinduced hepatotoxicity accounts for > 50% of overdose related acute liver failures in the United States [33] . The balance between conjugation and toxicity is determined largely by the degree to which the conjugating systems are saturated [19, 31, 33] . As saturation ensues, unconjugated APAP and NAPQI levels increase concomitantly. The toxic effects of NAPQI are buffered by glutathione (GSH), with which it reacts largely non-enzymatically [34] to form an APAP-GSH conjugate that is converted to secondary metabolites including APAP-NAC and APAP-Cys [21, 33] .
Detecting APAP and Mef metabolites in urine
Representative 1 H NMR spectra of APAP and Mef metabolites present in the urine of a heathy adult male following a single oral dose of APAP (1.0 g) and/or Mef (0.75 g) are presented in Fig. 2 , Panels A, B and C. Samples were taken at the end of the second one-hour interval following dosing, and NMR-peak areas reflect the average metabolite levels during that period. When APAP is taken alone (Panel A), the ratio of sulfonated to glucuronidated APAP (the S/G-ratio) is ∼1.2/1. The S/ G-ratio ratio calculated from the total amount of APAP-S and APAP-G collected over the first 8 h after dosing was ∼0.8, and is consistent with the ratios reported in previous clinical trials [21, 31] . The spectrum also reveals a minor quantity of APAP-Cys, which reports on the level of toxin (NAPQI) [21] . Mef metabolites include numerous oxidized and glucuronidated species [35, 36] . The major Mef metabolites in urine are the glucuronides of 3-OH-and 3-COOH-Mef [36] and the NMR peaks associated with these glucuronides are labelled in Panel B. When the drugs are taken simultaneously (Panel C), the APAP S/G-ratio decreases substantially (2.8-fold) relative to APAP alone, and the system compensates by increasing the APAP-G level ∼1.4-fold. Given the NMRsignal detection lower-limit (i.e., ∼1.0 μM metabolite), the spectrum further reveals a considerable Mef-induced increase (≥8-fold) in the level of APAP-NAC, which forms in response to increased level of NAPQI (see, Fig. 1 ) [21] . Increased APAP-NAC indicates that APAP levels have risen to the point that APAP cannot be glucuronidated quickly enough to avoid toxin formation, and the large fold-effect on APAP-NAC (≥8) relative to APAP-S (2.6) or APAP-G (1.3) suggests that the conjugating system may be near saturation.
Mef effects on APAP metabolism
To assess the influence of Mef on APAP metabolism, the distribution and quantities of APAP metabolites that accumulate in urine were determined at regular intervals over periods sufficient to recover > 90% of the APAP dose (Fig. 3A-D) . APAP (1.0 g) was taken either alone (white dots) or concomitantly with 0.75 g of Mef (black dots). The profiles reveal that Mef simultaneously suppresses APAP sulfonation and increases the levels of all other APAP metabolites. The ( ± )-Mef profiles for each metabolite begin separating immediately, achieve maximum separation maximum at 2-4 h, and coalesce near the sevenhour time point -this timeline is consistent with that for serum levels of orally administered Mef, which peak at ∼1.8 h and decrease to less than 10% of peak at seven hours [36] . To assess the extent to which APAP metabolism compensates for the Mef-induced loss in APAP-S, the difference between the (+) and (−) Mef APAP-S levels (i.e., Δ APAP-S ) was plotted vs the sum of the differences for all other metabolites (i.e., Δ APAP-G + Δ APAP-Cys + Δ APAP-Nac ). The plot (Fig. 4) reveals that losses in APAP-S correlate linearly with gains in the other metabolites. The slope of the correlation, 0.91, indicates that each µmole of APAP-S lost due to Mef produces a gain of 0.91 µmoles in compensating metabolites, and that virtually all excess APAP is conjugated and cleared in the intervals between sampling. Given that APAP conjugates share the same transporters (OATs and MDRs) in liver and kidney [37, 38] , the observed simultaneous decrease in APAP-S levels and increase in all other conjugates is difficult to explain on the basis of Mef-induced transporter inhibition. Moreover, transport inhibition is expected to delay APAP-S elimination without affecting overall exposure-neither of which is observed. Finally, an accumulation of APAP-S in plasma due to transporter inhibition is not de facto expected to result in quantitative conversion of APAP-S to alternative conjugates [19] . These contra-indications strongly suggest that the Mef-induced redistribution of APAP conjugates in urine is not likely the result of transporter inhibition.
Mef prevents first pass sulfonation
To assess the effects of Mef on APAP first-pass metabolism, APAP (1.0 g) and Mef (0 or 0.75 g) were taken together orally, and [20, 21, 31, 33] ; thus, conjugates that accumulate during the first 30 min are expected to reflect primarily first-pass metabolism, and to a lesser degree, systemic metabolism. Given that APAP-S accumulates as the systemic metabolism begins to dominate (see, Fig. 3 ), we can conclude that the contribution of systemic metabolism is negligible during the first 30 min, and thus that APAP sulfonation is essentially completely suppressed during first-pass metabolism. As might be expected, suppressing APAP-S leads to an increase in APAP-G levels.
Thorough suppression of first-pass APAP sulfonation may be of some clinical value. Intravenous (IV) APAP administration is considerably more effective in controlling pain than oral administration [39] and significantly reduces patient consumption of on-demand Fig. 3 . Mefinfluences APAP metabolism. APAP (1.0 g) was taken alone, white dots, or simultaneously with Mef (0.75 g), black dots. Drugs were taken orally with 275 ml water. Voided urine samples were collected at the indicated time intervals, sample volumes were determined, and APAP metabolite levels were quantitated using NMR (see, NMR Measurements in Methods). Data are plotted as total μmoles of metabolite in a given sample vs the time following drug administration. The influences of Mef on the following conjugates are shown: Panel A, APAP-sulfonate; Panel B, APAP-glucuronide; Panel C, APAP-cysteine; and Panel D, APAP-acetylcysteine. Fig. 4 . Mef-induced metabolic compensation among APAP metabolites. The difference between the (+) and (−) Mef levels of APAP-S(i.e., Δ APAP-S ) is plotted vs the sum of the differences for all other metabolites (i.e., Δ APAP-G + Δ APAP-Cys + Δ APAP-Nac ). The differences were calculated from the data shown in Fig. 3 . The correlation is linear, and its slope (0.91) indicates that virtually all of the APAP that is not sulfonated due to Mef is converted to other Mef conjugates and transported to urine. opioids in the peri-operative setting. The primary site of APAP's analgesic and antipyretic actions is believed to be the CNS [40, 41] . CNS APAP levels correlate linearly with plasma levels, and achieving plasma levels needed for rapid pain relief is challenging when the drug is given orally. Oral co-administration of APAP with Mef, and likely other NSAIDs, is expected to significantly increase unconjugated APAP plasma levels and, in theory, enhance the therapeutic effects of APAP. On this point, APAP and aspirin have long been considered synergisticconsider, for example, Excedrin Migraine, which contains both compounds. To our knowledge, a molecular mechanism for this synergy has not yet been published. The work described here offers a cogent rational for such synergy. Finally, UGT1A6 is primarily responsible for the glycosylation of APAP and is expressed at low levels in infants and neonates [42] . The lack of a compensating UGT pathway suggests that NSAID inhibition of sulfonation may be particularly effective in regulating the activities of APAP (and metabolites with similar SULT1A1/ UGT1A6-substrate profiles) in these populations.
Isoform-Specific inhibition suggests Mef acts allosterically
In designing an in vivo experiment to test whether the Mef induced inhibition of APAP sulfonation is likely allosteric, we reasoned that if a Mef-insensitive SULT isoform that exhibits high specificity for a urinedetectible metabolite could be identified, it would be possible to assess whether Mef inhibition in vivo correlates with its specificity toward the allosteric sites of Mef-sensitive and -insensitive isoforms.
The structure of the Mef-bound allosteric pocket of SULT1A1 [14] was used to identify a Mef-insensitive SULT isoform. When bound to 1A1, each of the two Mef benzyl-rings interacts with a different pair of planar SULT1A1 R-groups -H141/H144 and Y140/W155 (see, Fig. 6 ). Mutating any one residue typically attenuates Mef binding (five-to tenfold) but does not alter other initial-rate parameters [14] . Notably, the H141/H144-pair binds the single benzyl-ring of aspirin (acetylsalicylic acid) -an allosteric, NSAID inhibitor of SULT1A1 [14, 43] . In SULT2A1, one residue in each pair is substituted (H141F and H144/K) and the H141K substitution is non-conserved; hence, it seemed SULT2A1 might exhibit a substantially reduced affinity for Mef.
The sensitivity of SULTs 2A1 and 1A1 toward Mef inhibition were compared in classical initial-rate experiments. Reaction rates were determined as a function of Mef concentration at a saturating concentrations of PAPS and 1-hydroxypyrene, which undergoes a sulfonation dependent change in fluorescence [28] that was used to monitor reaction progress. The experimental design of the initial-rate experiments is described in Materials and Methods and the associated initialrate parameters are compiled in Table 1 . The affinity of Mef for SULT2A1 (K i = 14 ± 0.6 µM) is ∼520-fold weaker than its affinity for SULT1A1 (K i = 0.027 ± 0.001 µM). Thus, SULT2A1 seemed an excellent candidate for the proposed studies.
SULT2A1 expression is highest in liver, where it approaches that of SULT1A1 [8] , and its catalytic efficiency (k cat /K m ) toward DHEA (dehydroepiandrosterone) is uniquely high among SULTs; hence, 2A1′s common name: DHEA sulfotransferase [44] . DHEA is the most abundant circulating steroid in humans and is nearly 100% sulfonated in plasma [45] where it functions as a prohormone [46] . DHEA is available as an over-the-counter nutraceutical and the 1 H NMR signal of DHEA-S is readily detected in urine [47] .
To assess the in vivo Mef-sensitivity of SULT2A1, DHEA (75 mg) was administered orally with and without Mef (750 mg), and DHEA-S in urine was quantified at regular intervals over an 8 hr period using 1 H NMR. The drug administration protocol paralleled that for the APAP studies and is described in Materials and Methods. As is evident in Fig. 7 , Mef has no detectible effect on DHEA sulfonation. Thus, Mef inhibition In the presence of Mef, the APAP-S peak is suppressed beyond the limit of detection (∼100-fold). in vivo is isoform specific and consistent with its in vitro allosteric inhibition. It appears that Mef is binding at the NSAID allosteric site in vivo -a finding that suggests that the NSAID sites of other SULT isoforms may prove to be targets for controlling sulfotransferase-linked metabolism in humans. Catecholamine mediated neurotransmission and neuronal cell death [9, 48, 49] , thyroid hormone regulated energy metabolism [2] [3] [4] , estrogen linked adipogenesis [50] , HIV infection [51] , olfaction [52] … are but a few of the scenarios in which SULT isoform-specific inhibition might be used to correct disease-linked metabolic imbalances. The specificity of each SULT isoform centers on a different area of metabolism; hence, as targets, SULTs provide the opportunity to regulate 13 different, disease-relevant metabolic networks. Homology modelling indicates that each human SULT harbors at least one unique allosteric site [14, 16] . Each new allosteric binding-site promises a target that can be used to regulate a specific area of SULT biology.
Conclusions
Mef inhibits SULT1A1 in vivo in an isoform specific manner that is consistent with its binding at the NSAID allosteric site -this finding opens the door to using Mef (or other NSAIDs) to control SULT1A1 activity in humans and, more broadly, to targeting SULT allosteric sites to control specific aspects of SULT biology; second, Mef completely suppresses APAP sulfonation during first pass metabolism, which may prove to be of therapeutic value; finally, the work reveals that APAP that is not sulfonated due to Mef is shifted nearly entirely to other conjugates, including an ∼7-fold increase in NAPQI levels -a fact that should be born in mind when administering APAP with Mef or other NSAIDs.
